

IN THE CLAIMS:

1. An isolated Cadherin-like asymmetry protein-5 (CLASP-5) polynucleotide, wherein said polynucleotide is
 - (a) a polynucleotide that has the sequence of SEQ ID NO:1 or
 - (b) a polynucleotide that hybridizes under stringent hybridization conditions comprising wash conditions of 0.2X SSC and 0.1% SDS at 45°C to (a) and encodes a polypeptide having the sequence of SEQ ID NO:2 or an allelic variant or homologue of a polypeptide having the sequence of SEQ ID NO:2; or
 - (c) a polynucleotide that hybridizes under stringent hybridization conditions comprising wash conditions of 0.2X SSC and 0.1% SDS at 45°C to (a) and encodes a polypeptide with at 25 contiguous residues of the polypeptide of SEQ ID NO:2; or
 - (d) a polynucleotide that hybridizes under stringent hybridization conditions comprising wash conditions of 0.2X SSC and 0.1% SDS at 45°C to (a) and has at least 12 contiguous bases identical to or exactly complementary to SEQ ID NO:1.
4. An isolated Cadherin-like asymmetry protein-5 (CLASP-5) polynucleotide comprising a nucleotide sequence that has at least 90% percent identity to SEQ ID NO:1.
12. An antisense oligonucleotide complementary to a messenger RNA comprising SEQ ID NO:1 and encoding Cadherin-like asymmetry protein-5 (CLASP-5), wherein the oligonucleotide inhibits the expression of CLASP-5.
13. An isolated DNA that encodes a Cadherin-like asymmetry protein-5

claim 1 and a pharmaceutically acceptable carrier